The Numbers
The Wegovy label includes acute gallbladder disease as a warning, and SELECT trial data point to a small absolute increase in gallbladder-related events.
The Mechanism
The mechanism is biliary chemistry: when body fat drops fast, cholesterol concentration in bile goes up, and slower gut motility lets gallstones form.
The same risk exists with bariatric surgery, very-low-calorie diets, and other rapid-weight-loss methods. GLP-1 medicines can contribute too. The practical way to understand it is this: gallbladder risk can rise for two reasons at once. The medicine changes digestion, and fast weight loss changes bile.
What this means
References2 sources
How to read these sources
This article uses primary sources and reviews to separate mechanism, human evidence, and context.
- Human Trial
Massachusetts Medical SocietySemaglutide and Cardiovascular Outcomes in Obesity without Diabetes Read source
Used Here ForGrounding the gallbladder question in the SELECT trial's safety data.
Good ForTrial safety data on gallbladder-related events with semaglutide 2.4 mg.
Not ForDiagnosing gallbladder disease or giving personal treatment advice.
New England Journal of Medicine 389(24):2221-2232 - Official Label
FDA-approved prescribing information (Wegovy)
U.S. Food and Drug Administration / Novo NordiskWEGOVY (semaglutide) prescribing information: 5.3 Acute Gallbladder Disease Read source
Used Here ForChecking the approved label's acute gallbladder disease warning.
Good ForThe FDA-approved warning on gallbladder risk.
Not ForDiagnosing gallbladder disease or giving personal treatment advice.
FDA-approved labeling, DailyMed (National Library of Medicine), updated June 18, 2026